Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 598-603

  Miyake, Hideaki ^a   Kurahashi, Toshifumi ^a   Takenaka, Atsushi ^a   Inoue, Taka aki ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

Interferon ; Interleukin 2; Metastasis; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; IMUNACE; INTERLEUKIN 2; OIF; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; JAPANESE; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 70350490508     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.07.023     Document Type: Article

References (20)

1. Figlin R.A. Renal cell carcinoma: Management of advanced disease. J Urol 161 (1999) 381-387
2. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
3. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
4. Bellmunt J., Montagut C., Albiol S., et al. Present strategies in the treatment of metastatic renal cell carcinoma: An update on molecular targeting agents. BJU Int 99 (2007) 274-280
5. Lane B.R., Rini B.I., Novick A.C., et al. Targeted molecular therapy for renal cell carcinoma. Urology 69 (2007) 3-10
6. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
7. Akaza H., Tsukamoto T., Murai M., et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37 (2007) 755-762
8. Miyake H., Hara I., Sakai I., et al. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: A preliminary report. Int J Clin Oncol 10 (2005) 338-341
9. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2005) 289-296
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
11. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
12. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 338 (1998) 1272-1278
13. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
14. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized Phase III trial of high-dose interleukin-2 vs. subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
15. Atzpodien J., Hoffmann R., Franzke M., et al. Thirteen-year, long-term efficacy of interferon-α and interleukin-2 based home therapy in patients with advanced renal cell carcinoma. Cancer 95 (2002) 1045-1050
16. Parton M., Gore M., and Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24 (2006) 5584-5592
17. Verra N., Jansen R., Groenewegen G., et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-αa in patients with progressive metastatic renal cell carcinoma. Br J Cancer 88 (2003) 1346-1351
18. Buzio C., Andrulli S., Santi R., et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer 92 (2001) 2286-2296
19. Clark J.I., Gaynor E.R., Martone B., et al. Daily subcutaneous ultra-low-dose interleukin-2 with daily low-dose interferon-α in patients with advanced renal cell carcinoma. Clin Cancer Res 5 (1999) 2374-2380
20. Casamassima A., Picciariello M., Quaranta M., et al. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173 (2005) 52-55